EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeit

Severe Disease Activation after Fingolimod Discontinuation in a Pediatric Multiple Sclerosis Patient: A Case Report and Literature Review

Brenda Huppke, Heike de Vries, Astrid Blaschek, Peter Huppke iD

Neuropediatrics · 01.04.2025 · 56 (02) · 147-150

DOI: 10.1055/a-2496-5294 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Neuropediatrics, erschienen am 01.04.2025. Verfasst von Brenda Huppke und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Neurology, Jena University Hospital, Jena, Germany. Hauptthemen laut MEDLINE: Fingolimod Hydrochloride, Immunosuppressive Agents, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adult reports of unexpected severe disease worsening, often termed “rebound,” shortly after discontinuing fingolimod in a subset of patients with multiple sclerosis (MS), have grown over the last decade. This phenomenon, however, remains poorly described in pediatric MS patients. We present findings of a 15-year-old who experienced a debilitating relapse 4 weeks after stopping fingolimod to switch to ocrelizumab. Imaging revealed multiple large new lesions far exceeding any previously observed activity level in the patient. Despite prompt high-dose corticosteroids, plasma exchange, and prolonged rehabilitation therapy, significant residual deficits involving cognition, balance, and vision remain from the attack. This case underscores that pediatric MS patients are also at risk of severe disease deterioration after fingolimod withdrawal and require close monitoring when switching therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fingolimod HydrochlorideImmunosuppressive AgentsMultiple SclerosisMultiple Sclerosis, Relapsing-RemittingAdolescentHumansAntibodies, Monoclonal, HumanizedDisease Progression

Substanzen

Antibodies, Monoclonal, HumanizedFingolimod HydrochlorideImmunosuppressive Agentsocrelizumab

Autor:innen und Institutionen

  • Department of Pediatric Neurology, Jena University Hospital, Jena, Germany.
  • Department of Pediatric Neurology and Developmental Medicine and LMU Center for Children with Medical Complexity, Ludwig-Maximilians-Universität München, Dr. von Hauner Children's Hospital, LMU Hospital, Munich, Germany.
  • Center for Rare Diseases, Jena University Hospital, Jena, Germany.

ORCID-Profile: Peter Huppke

Zitieren

APA

Huppke, B., Vries, H., Blaschek, A., & Huppke, P. (2025). Severe Disease Activation after Fingolimod Discontinuation in a Pediatric Multiple Sclerosis Patient: A Case Report and Literature Review. Neuropediatrics, 56(02), 147-150. https://doi.org/10.1055/a-2496-5294

Vancouver

Huppke B, Vries H, Blaschek A, Huppke P. Severe Disease Activation after Fingolimod Discontinuation in a Pediatric Multiple Sclerosis Patient: A Case Report and Literature Review. Neuropediatrics. 2025;56(02):147-150. doi:10.1055/a-2496-5294

BibTeX
@article{Huppke2025,
  author = {Huppke, Brenda and Vries, Heike de and Blaschek, Astrid and Huppke, Peter},
  title = {Severe Disease Activation after Fingolimod Discontinuation in a Pediatric Multiple Sclerosis Patient: A Case Report and Literature Review},
  journal = {Neuropediatrics},
  year = {2025},
  volume = {56},
  number = {02},
  pages = {147--150},
  doi = {10.1055/a-2496-5294}
}
Kostenlos starten →